Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644211 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Thrombocythemia and Polycythemia Vera
A Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT04644211 is a Phase 2 study of Polycythemia Vera and Essential Thrombocythemia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT04644211, a Phase 2 study of Polycythemia Vera and Essential Thrombocythemia, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). \- This research study involves the study drug Ruxolitinib.
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth-Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General North Shore Cancer Center - Danvers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2034-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04644211
The ClinicalTrials.gov registry entry for NCT04644211 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (82% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT04644211 reports 4 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04644211 about?
NCT04644211 is a clinical study titled "Ruxolitinib in Thrombocythemia and Polycythemia Vera". This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). \- This research study involves the study drug Ruxolitinib.
What is the current status of trial NCT04644211?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-03-21. Estimated completion is 2034-07.
What conditions does trial NCT04644211 study?
This clinical trial studies the following conditions: Polycythemia Vera, Essential Thrombocythemia.
What interventions are being tested in trial NCT04644211?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT04644211?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04644211 being conducted?
This trial has 4 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.